298 related articles for article (PubMed ID: 15630049)
41. Role of prostanoids in regulation of the renin-angiotensin-aldosterone system by salt intake.
Höcherl K; Kammerl MC; Schumacher K; Endemann D; Grobecker HF; Kurtz A
Am J Physiol Renal Physiol; 2002 Aug; 283(2):F294-301. PubMed ID: 12110513
[TBL] [Abstract][Full Text] [Related]
42. Cyclooxygenase 2 and neuronal nitric oxide synthase expression in the renal cortex are not interdependent in states of salt deficiency.
Castrop H; Kammerl M; Mann B; Jensen BL; Krämer BK; Kurtz A
Pflugers Arch; 2000 Dec; 441(2-3):235-40. PubMed ID: 11211108
[TBL] [Abstract][Full Text] [Related]
43. Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence.
Muscará MN; Vergnolle N; Lovren F; Triggle CR; Elliott SN; Asfaha S; Wallace JL
Br J Pharmacol; 2000 Apr; 129(7):1423-30. PubMed ID: 10742298
[TBL] [Abstract][Full Text] [Related]
44. The role of nitric oxide and the renin-angiotensin system in salt-restricted Dahl rats.
Kataoka H; Otsuka F; Ogura T; Yamauchi T; Kishida M; Takahashi M; Mimura Y; Makino H
Am J Hypertens; 2001 Mar; 14(3):276-85. PubMed ID: 11281241
[TBL] [Abstract][Full Text] [Related]
45. [COX-2 inhibitor non-steroidal anti-inflammatory drugs, myth or reality?].
Peretz A
Rev Med Brux; 2001 Sep; 22(4):A377-80. PubMed ID: 11680204
[TBL] [Abstract][Full Text] [Related]
46. Role of macula densa cyclooxygenase-2 in renovascular hypertension.
Hartner A; Cordasic N; Goppelt-Struebe M; Veelken R; Hilgers KF
Am J Physiol Renal Physiol; 2003 Mar; 284(3):F498-502. PubMed ID: 12429553
[TBL] [Abstract][Full Text] [Related]
47. A novel mechanism contributing to development of Dahl salt-sensitive hypertension: role of the transient receptor potential vanilloid type 1.
Wang Y; Wang DH
Hypertension; 2006 Mar; 47(3):609-14. PubMed ID: 16365187
[TBL] [Abstract][Full Text] [Related]
48. Telmisartan improves endothelial dysfunction and renal autoregulation in Dahl salt-sensitive rats.
Satoh M; Haruna Y; Fujimoto S; Sasaki T; Kashihara N
Hypertens Res; 2010 Feb; 33(2):135-42. PubMed ID: 19927153
[TBL] [Abstract][Full Text] [Related]
49. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans.
Werner U; Werner D; Rau T; Fromm MF; Hinz B; Brune K
Clin Pharmacol Ther; 2003 Aug; 74(2):130-7. PubMed ID: 12891223
[TBL] [Abstract][Full Text] [Related]
50. Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: effect of celecoxib and rofecoxib.
Patti R; Gumired K; Reddanna P; Sutton LN; Phillips PC; Reddy CD
Cancer Lett; 2002 Jun; 180(1):13-21. PubMed ID: 11911965
[TBL] [Abstract][Full Text] [Related]
51. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Weir MR; Sperling RS; Reicin A; Gertz BJ
Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
[TBL] [Abstract][Full Text] [Related]
52. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker.
Nagase M; Shibata S; Yoshida S; Nagase T; Gotoda T; Fujita T
Hypertension; 2006 Jun; 47(6):1084-93. PubMed ID: 16636193
[TBL] [Abstract][Full Text] [Related]
53. Upregulation of cortical COX-2 in salt-sensitive hypertension: role of angiotensin II and reactive oxygen species.
Jaimes EA; Zhou MS; Pearse DD; Puzis L; Raij L
Am J Physiol Renal Physiol; 2008 Feb; 294(2):F385-92. PubMed ID: 18094033
[TBL] [Abstract][Full Text] [Related]
54. Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress.
Zhou MS; Jaimes EA; Raij L
Hypertension; 2004 Aug; 44(2):186-90. PubMed ID: 15238570
[TBL] [Abstract][Full Text] [Related]
55. Effects of imidapril on NOS expression and myocardial remodelling in failing heart of Dahl salt-sensitive hypertensive rats.
Kobayashi N; Higashi T; Hara K; Shirataki H; Matsuoka H
Cardiovasc Res; 1999 Dec; 44(3):518-26. PubMed ID: 10690283
[TBL] [Abstract][Full Text] [Related]
56. COX-1 and COX-2 inhibitors.
Hawkey CJ
Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):801-20. PubMed ID: 11566042
[TBL] [Abstract][Full Text] [Related]
57. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S401-13. PubMed ID: 12416790
[TBL] [Abstract][Full Text] [Related]
58. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
[TBL] [Abstract][Full Text] [Related]
59. Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension: mechanisms of renal artery endothelial dysfunction and role of endothelin for vascular hypertrophy and Glomerulosclerosis.
Barton M; Vos I; Shaw S; Boer P; D'Uscio LV; Gröne HJ; Rabelink TJ; Lattmann T; Moreau P; Lüscher TF
J Am Soc Nephrol; 2000 May; 11(5):835-845. PubMed ID: 10770961
[TBL] [Abstract][Full Text] [Related]
60. Renal effects on a solitary kidney of specific inhibition of cyclooxygenease-2 after 24 h of complete ureteric obstruction in rats.
Oztürk H; Ozdemir E; Otcu S; Büyükbayram H; Ihsan Dokucu A
Urol Res; 2002 Sep; 30(4):223-6. PubMed ID: 12202939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
